[go: up one dir, main page]

MX2013000539A - Nuevas formulaciones de analogos 14-epi de la vitamina d. - Google Patents

Nuevas formulaciones de analogos 14-epi de la vitamina d.

Info

Publication number
MX2013000539A
MX2013000539A MX2013000539A MX2013000539A MX2013000539A MX 2013000539 A MX2013000539 A MX 2013000539A MX 2013000539 A MX2013000539 A MX 2013000539A MX 2013000539 A MX2013000539 A MX 2013000539A MX 2013000539 A MX2013000539 A MX 2013000539A
Authority
MX
Mexico
Prior art keywords
epi
analogues
vitamin
new formulations
formulations
Prior art date
Application number
MX2013000539A
Other languages
English (en)
Inventor
Remi Delansorne
Original Assignee
Hybrigenics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/836,974 external-priority patent/US20120015913A1/en
Priority claimed from EP10305783A external-priority patent/EP2407152A1/en
Application filed by Hybrigenics Sa filed Critical Hybrigenics Sa
Publication of MX2013000539A publication Critical patent/MX2013000539A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona las formulaciones de los análogos 14-epi de la vitamina D, tal como inecalcitol, que proporcionan el perfil de absorción mejorado.
MX2013000539A 2010-07-15 2011-07-13 Nuevas formulaciones de analogos 14-epi de la vitamina d. MX2013000539A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/836,974 US20120015913A1 (en) 2010-07-15 2010-07-15 Formulations of 14-EPI-Analogues of Vitamin D
EP10305783A EP2407152A1 (en) 2010-07-15 2010-07-15 Formulations of 14-epi-analogues of vitamin D
PCT/EP2011/061973 WO2012007512A1 (en) 2010-07-15 2011-07-13 New formulations of 14 - epi -analogues of vitamin d

Publications (1)

Publication Number Publication Date
MX2013000539A true MX2013000539A (es) 2013-04-11

Family

ID=44281019

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000539A MX2013000539A (es) 2010-07-15 2011-07-13 Nuevas formulaciones de analogos 14-epi de la vitamina d.

Country Status (18)

Country Link
EP (2) EP2407154B1 (es)
JP (2) JP5836372B2 (es)
KR (2) KR101821441B1 (es)
CN (2) CN103096877B (es)
AU (2) AU2011278352B2 (es)
BR (2) BR112013000930A2 (es)
CA (2) CA2805198C (es)
DK (2) DK2407155T3 (es)
ES (2) ES2401715T3 (es)
HR (2) HRP20130093T1 (es)
IL (2) IL224191A (es)
MX (1) MX2013000539A (es)
NZ (2) NZ606679A (es)
PL (2) PL2407155T3 (es)
PT (2) PT2407155E (es)
SG (2) SG187071A1 (es)
SI (2) SI2407155T1 (es)
WO (3) WO2012007517A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2407155T1 (sl) * 2010-07-15 2013-04-30 Hybrigenics S.A. Preparati na osnovi inekalcitola
US20120015913A1 (en) 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
EP2908827A4 (en) * 2012-10-19 2016-08-31 Celus Pharmaceuticals Inc VITAMIN D ANALOGUE FOR THE TREATMENT OF A NEUROLOGICAL DISEASE
US10111896B2 (en) * 2014-06-19 2018-10-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse
TWI749016B (zh) * 2016-06-08 2021-12-11 董宇紅 具有奇數碳的脂類化合物及其作為醫藥組合物或者營養補充劑的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0707566T3 (da) * 1993-07-09 2000-09-04 Theramex Hidtil ukendte strukturelle analoger til vitamin D
JPH10111593A (ja) * 1996-10-04 1998-04-28 Asahi Optical Co Ltd 複写機の変倍光学装置
US5936105A (en) 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
GB0305332D0 (en) 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
PT103177A (pt) 2003-09-24 2005-03-31 Bioxell Spa 1-alfa-fluoro-25-hidroxi-16,23e-dieno-26,27-bis-homo-20-epi-colecalciferol, seus sais ou esteres e sua utilizacao no fabrico de medicamentos
GB0423091D0 (en) * 2004-10-19 2004-11-17 Leuven K U Res & Dev Bioactive vitamin d analogues
US20070093458A1 (en) * 2005-07-18 2007-04-26 Anchel Schwartz Preparation of paricalcitol and crystalline forms thereof
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
JP2010111593A (ja) * 2008-11-04 2010-05-20 Teijin Pharma Ltd １４−エピ−１９−ノルプレビタミンｄ３誘導体
BRPI1009056A2 (pt) * 2009-05-20 2020-06-02 Hybrigenics Sa Uso de inecalcitol
SI2407155T1 (sl) * 2010-07-15 2013-04-30 Hybrigenics S.A. Preparati na osnovi inekalcitola

Also Published As

Publication number Publication date
WO2012007517A1 (en) 2012-01-19
AU2011278346A1 (en) 2013-03-07
WO2012007570A2 (en) 2012-01-19
CA2805198C (en) 2018-07-31
PL2407154T3 (pl) 2013-04-30
PT2407155E (pt) 2013-04-03
ES2401715T3 (es) 2013-04-23
AU2011278352B2 (en) 2016-07-21
CN103096877B (zh) 2017-09-22
NZ606678A (en) 2014-11-28
ES2398640T3 (es) 2013-03-20
EP2407154A1 (en) 2012-01-18
NZ606679A (en) 2014-07-25
SG187071A1 (en) 2013-02-28
CN103096876A (zh) 2013-05-08
JP5836372B2 (ja) 2015-12-24
WO2012007512A1 (en) 2012-01-19
CA2805203A1 (en) 2012-01-19
JP2013531023A (ja) 2013-08-01
EP2407155B1 (en) 2012-12-26
DK2407154T3 (da) 2013-03-04
CA2805198A1 (en) 2012-01-19
SI2407155T1 (sl) 2013-04-30
EP2407154B1 (en) 2012-11-07
AU2011278346B2 (en) 2016-04-07
JP2013531024A (ja) 2013-08-01
RU2013106492A (ru) 2014-08-20
IL224191A (en) 2016-03-31
AU2011278352A1 (en) 2013-03-07
KR101821441B1 (ko) 2018-01-23
DK2407155T3 (da) 2013-04-02
SG187072A1 (en) 2013-03-28
JP5836373B2 (ja) 2015-12-24
KR101821440B1 (ko) 2018-01-23
EP2407155A1 (en) 2012-01-18
PL2407155T3 (pl) 2013-05-31
BR112013000941A2 (pt) 2017-10-31
RU2013106493A (ru) 2014-08-20
KR20130103709A (ko) 2013-09-24
IL224192A (en) 2016-02-29
PT2407154E (pt) 2013-02-15
BR112013000930A2 (pt) 2017-10-31
HRP20130237T1 (hr) 2013-04-30
KR20130089249A (ko) 2013-08-09
HRP20130093T1 (hr) 2013-02-28
WO2012007570A3 (en) 2012-05-24
SI2407154T1 (sl) 2013-03-29
CN103096877A (zh) 2013-05-08

Similar Documents

Publication Publication Date Title
IN2012DN06714A (es)
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
JO3755B1 (ar) تركيبات تستوستيرون
HK1209159A1 (en) Methods of decellularizing bone
MY157341A (en) Methods and compositions for treating lung cancer
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
IN2015DN02645A (es)
CO6761388A2 (es) Composiciones pharmaceuticas que comprenden alisporivir
IN2015DN02643A (es)
WO2012139074A3 (en) Migrastatins and uses thereof
MX360017B (es) Formulación de aroma y fragancia (iv).
MX2013008559A (es) Derivados de leptina.
IN2015DN02644A (es)
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
UA80812U (en) ETHYL 6-THIOXO-3-(2-FURYLMETHYL)-7-CYANO-1,3,4,6-2H-PYRIDO[1,2-a][1,3,5]TRIAZINE -9-CARBOXYLATE
UA60476U (ru) Применение (1,1-диоксотиолан-3-ил)дитиокарбамата калия в качестве антимикробного средства
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA72478U (ru) Применение полентара как средства фригопротекторного действия
UA96059C2 (ru) Применение липина как средства фригопротекторного действия
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства
IN2015KN00386A (es)
ES2421810A2 (es) Intermedios utiles para la sintesis de fexofenadina, procedimientos para su preparacion y para la preparacion de fexofenadina

Legal Events

Date Code Title Description
FG Grant or registration